NEW YORK, March 17, 2016 (GLOBE NEWSWIRE) -- Nasdaq (Nasdaq:NDAQ) announced that trading of Hutchison China MediTech Limited (“Chi-Med”) (Nasdaq:HCM) commenced on The Nasdaq Stock Market on March 17, 2016.
A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/325421b1-32cd-41a5-bf79-c5aaa10c965a
Chi-Med is a China-based biopharmaceutical company aiming to become a global leader in the discovery and development of targeted, small molecule kinase inhibitors to treat a wide range of solid tumors, blood cancers and immune diseases. Its broad pipeline includes seven clinical-stage product candidates against molecular targets such as c-Met, Syk, VEGFR, and EGFR with first- or best-in-class potential. Chi-Med is conducting a total of 20 active clinical trials in various countries, including two late-stage studies with AstraZeneca in the U.S. and Eli Lilly in China advancing toward potential new drug applications.
“Today is an important milestone for Chi-Med as we go public in the U.S. market,” said Simon To, Executive Director and Chairman of Chi-Med. “Our R&D is focused on addressing the shortcomings of many of the currently approved kinase inhibitors, specifically the off-target toxicities that limit drug exposure and efficacy. We hope our efforts will result in life-saving therapies for the many patients around the world with few or no treatment options.”
“We welcome Chi-Med as they continue to advance their rapidly growing pipeline,” said Bob McCooey, Senior Vice President, Listing Services, Nasdaq. “As the venue of choice for innovators and visionaries around the globe, we are excited to be the strategic partner that supports revolutionary companies as they take on the world stage.”
The information contained above is provided for informational and educational purposes only, and nothing contained herein should be construed as investment advice, either on behalf of a particular security or an overall investment strategy. Information about the company is provided by the company or comes from the company’s public filings and is not independently verified by Nasdaq. Neither Nasdaq nor any of its affiliates makes any recommendation to buy or sell any security or any representation about the financial condition of any company. Statements regarding Nasdaq-listed companies are not guarantees of future performance. Actual results may differ materially from those expressed or implied. Past performance is not indicative of future results. Investors should undertake their own due diligence and carefully evaluate companies before investing. ADVICE FROM A SECURITIES PROFESSIONAL IS STRONGLY ADVISED.
Chi-Med is a China-based, globally-focused healthcare group which researches, develops, manufactures and sells pharmaceuticals and health-related consumer products. Its Innovation Platform focuses on discovering and developing innovative therapeutics in oncology and autoimmune diseases for the global market. Its Commercial Platform manufactures, markets, and distributes prescription drugs and consumer health products in China. Chi-Med is majority owned by the multinational conglomerate CK Hutchison Holdings Limited (SEHK: 0001). For more information, please visit: http://www.chi-med.com
Nasdaq (Nasdaq:NDAQ) is a leading provider of trading, clearing, exchange technology, listing, information and public company services across six continents. Through its diverse portfolio of solutions, Nasdaq enables customers to plan, optimize and execute their business vision with confidence, using proven technologies that provide transparency and insight for navigating today's global capital markets. As the creator of the world's first electronic stock market, its technology powers more than 70 marketplaces in 50 countries, and 1 in 10 of the world's securities transactions. Nasdaq is home to more than 3,700 listed companies with a market value of approximately $9.6 trillion and more than 10,000 corporate clients. To learn more, visit: nasdaq.com/ambition or business.nasdaq.com
- NDAQG -